Publication
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (15)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 15
- cancerMalignant Neoplasmcivic_curation1.00
- cancerPeritoneal Mesothelial Neoplasmcivic_curation1.00
- drugCytoreductive Surgerycivic_curation1.00
- drugErlotinibcivic_curation1.00
- drugHyperthermic Intraperitoneal Chemotherapycivic_curation1.00
- geneEGFRcivic_curation1.00
- variantEGFR C797Ycivic_curation1.00
- variantEGFR E734Qcivic_curation1.00
- variantEGFR E868Gcivic_curation1.00
- variantEGFR L858Rcivic_curation1.00
- variantEGFR Mutationcivic_curation1.00
- variantEGFR R831Hcivic_curation1.00
- variantEGFR T785Acivic_curation1.00
- variantEGFR W731Lcivic_curation1.00
- variantEGFR Y801Hcivic_curation1.00
Curated evidence
Evidence citing this paper (9)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 20942962
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR C797Y1 | ||||||||
| Erlotinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID4658In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR C797Y demonstrated increased EGFR phosphotyrosine after … (full text at CIViC) PMID 20942962 · Foster et al., 2010 · Open in CIViC | civic |
| EGFR E734Q1 | ||||||||
| Erlotinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID4656In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR E734Q demonstrated increased EGFR phosphotyrosine after … (full text at CIViC) PMID 20942962 · Foster et al., 2010 · Open in CIViC | civic |
| EGFR E868G1 | ||||||||
| Erlotinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID4301In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR E868G demonstrated increased EGFR phosphotyrosine after … (full text at CIViC) PMID 20942962 · Foster et al., 2010 · Open in CIViC | civic |
| EGFR L858R1 | ||||||||
| Erlotinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID5922In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR L858R demonstrated increased EGFR phosphotyrosine after … (full text at CIViC) PMID 20942962 · Foster et al., 2010 · Open in CIViC | civic |
| EGFR R831H1 | ||||||||
| Erlotinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID4279In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR R831H demonstrated increased EGFR phosphotyrosine after … (full text at CIViC) PMID 20942962 · Foster et al., 2010 · Open in CIViC | civic |
| EGFR T785A1 | ||||||||
| Erlotinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID4657In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR T785A demonstrated increased EGFR phosphotyrosine after … (full text at CIViC) PMID 20942962 · Foster et al., 2010 · Open in CIViC | civic |
| EGFR W731L1 | ||||||||
| Erlotinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID4655In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR W731L demonstrated increased EGFR phosphotyrosine after … (full text at CIViC) PMID 20942962 · Foster et al., 2010 · Open in CIViC | civic |
| EGFR Y801H1 | ||||||||
| Erlotinib | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID4659In an in vitro study performed after identification of the mutation in a malignant peritoneal mesothelioma patient, COS-7 cells expressing EGFR Y801H demonstrated increased EGFR phosphotyrosine after … (full text at CIViC) PMID 20942962 · Foster et al., 2010 · Open in CIViC | civic |
| EGFR Mutation1 | ||||||||
| Cytoreductive Surgery + Hyperthermic Intraperitoneal ChemotherapyCombination | Peritoneal Mesothelial NeoplasmALIAS | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID592325 patients with metastatic peritoneal mesothelioma were treated with surgical cytoreduction consolidated with intraperitoneal hyperthermic chemotherapy (CRS/IPHC). 8 of the patients carried EGFR muta… (full text at CIViC) PMID 20942962 · Foster et al., 2010 · Open in CIViC | civic |